Dublin, Ireland, July 27, 2017 – ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2017.

Highlights  

·       Record net business wins of $563 million; net book to bill of 1.31. Backlog of business grew 10% year on year to $4.44 billion.

·       Net revenue increased 5.0% to $431 million compared to the same quarter last year, 6.0% on a constant currency basis.

·       Top customer revenue concentration reduced from 28% of revenue in Q2 2016 to 19.9% in Q2 2017.

·       Income from operations, before non-recurring charges, increased 10% to 19.9% of revenue compared to the same quarter last year.

·       Earnings per share, before non-recurring charges, increased 15% to $1.31 year on year.

·       Guidance increased to reflect the acquisition of Mapi Group and revised tax rate for the second half of 2017.  Earnings guidance increased from a range of $5.06 – $5.26 to $5.18 – $5.38. Revenue guidance increased from a range of $1.70 – $1.75 billion to $1.74 – $1.77 billion.

To read more, please click HERE.